Metabolic Syndrome: Definition and Clinical Significance

Definition and Pathophysiology

Metabolic syndrome is a clustering of cardiometabolic abnormalities centred on abdominal adiposity, insulin resistance, dyslipidaemia, elevated blood pressure and impaired glucose regulation. Diagnosis is based on the coexistence of defined clinical and laboratory components; the diagnostic criteria themselves are not reproduced in the available source material. Waist circumference is particularly important because intra-abdominal, or visceral, adipose tissue is more closely related to insulin resistance and the risk of diabetes and cardiovascular disease than total adiposity alone. The waist circumference associated with risk varies among populations, reflecting differences in fat distribution and ethnicity.

Abdominal obesity is a major driving force. Visceral adipose tissue is metabolically active and produces proinflammatory mediators. Increased free-fatty-acid flux and impaired insulin action promote hepatic triglyceride-rich lipoprotein synthesis and reduce triglyceride-rich lipoprotein and remnant clearance. The resulting atherogenic dyslipidaemia is characterized by elevated triglycerides, reduced HDL cholesterol and increased small, dense LDL particles. Increased apoB-containing particles and remnants may provide a more accurate assessment of atherogenic burden than LDL cholesterol alone in patients with diabetes.

Insulin resistance is accompanied by compensatory hyperinsulinaemia and, with progression, hyperglycaemia and pancreatic β-cell dysfunction. These abnormalities initiate self-perpetuating metabolic and inflammatory pathways that injure the vasculature, heart and kidneys. Advanced glycation end-products activate inflammatory and profibrotic signalling through their receptor. Endothelial dysfunction, increased vascular stiffness, impaired coronary circulation, vascular calcification and myocardial fibrosis further accelerate cardiovascular and renal injury.

Adipokine imbalance contributes to insulin resistance, β-cell failure, endothelial dysfunction and atherosclerosis. Ectopic fat deposited around or within the heart and kidneys may exert direct compressive effects and releases additional inflammatory and profibrotic mediators. Perinephric fat is associated with hypertension and blood-pressure variability, while obesity and hypertension together promote left-ventricular hypertrophy and kidney injury.

The syndrome is therefore both a clinical risk-factor cluster and a marker of broader metabolic dysfunction. Associated abnormalities may include increased apoB and apoC-III, uric acid, fibrinogen, plasminogen activator inhibitor 1, serum viscosity, asymmetric dimethylarginine, homocysteine, white blood cell count, proinflammatory cytokines and C-reactive protein. Increased urinary albumin/creatinine ratio reflects altered endothelial and renal pathophysiology in insulin resistance.

Metabolic Dysfunction-Associated Fatty Liver Disease

Insulin resistance increases free-fatty-acid delivery to the liver and reduces intrahepatic fatty-acid oxidation. Triglyceride synthesis and hepatocellular lipid accumulation consequently increase, with variable inflammation and oxidative stress. Metabolic dysfunction-associated fatty liver disease affects approximately 10% of non-obese individuals and up to 65% of patients with metabolic syndrome. A substantial proportion develop metabolic dysfunction-associated steatohepatitis, which has a more prominent inflammatory component and may progress to cirrhosis and end-stage liver disease. Metabolic dysfunction-associated fatty liver disease is also independently related to cardiovascular disease, particularly coronary artery disease.

Hyperuricaemia and Endothelial Dysfunction

Insulin resistance impairs renal tubular handling of uric acid and may contribute to hyperuricaemia. Uric acid may promote hypertension through effects on the endothelium. Increased asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, provides an additional potential mechanism for endothelial dysfunction. Albuminuria may similarly reflect vascular and endothelial abnormalities in the insulin-resistant state.

Associated Conditions

Polycystic ovary syndrome is strongly associated with insulin resistance and metabolic syndrome. Obstructive sleep apnoea commonly coexists with obesity, hypertension, impaired glucose tolerance, increased proinflammatory cytokines and insulin resistance. It may predict metabolic syndrome even without excess adiposity, and insulin resistance is more severe in patients with sleep apnoea than in weight-matched controls. Continuous positive airway pressure improves insulin sensitivity in patients with obstructive sleep apnoea.

Clinical Presentation and Symptoms

Metabolic syndrome is usually clinically silent. The most frequent examination findings are an increased waist circumference and elevated blood pressure. Either finding should prompt assessment for associated biochemical abnormalities.

Less commonly, patients may have lipoatrophy or acanthosis nigricans. These findings indicate severe insulin resistance, in which the other components of metabolic syndrome are generally particularly prevalent.

Symptoms may arise from associated conditions rather than from the syndrome itself. The history should specifically assess for symptoms suggestive of obstructive sleep apnoea in all patients and for polycystic ovary syndrome in premenopausal women. Cardiovascular disease, cerebrovascular disease, peripheral vascular disease and heart failure may develop as clinical consequences of the risk-factor cluster.

Some individuals with obesity and metabolic syndrome report reduced energy and drive, poor concentration, reduced exercise capacity, diminished quality of life, low self-esteem and social isolation. Increased fat mass, central fat deposition, reduced lean body mass and reduced maximum oxygen uptake may accompany impaired cardiac structure and function.

Evaluation and Physical Examination

Evaluation begins with a focused medical history and direct assessment of the syndrome’s clinical components.

History

The history should address:

• Symptoms of obstructive sleep apnoea in all patients.

• Features suggesting polycystic ovary syndrome and anovulation in premenopausal women.

• Personal history of cardiovascular disease, hypertension, dysglycaemia, dyslipidaemia, kidney disease and fatty liver disease.

• Family history of cardiovascular disease and diabetes mellitus.

• Dietary pattern, physical activity, weight trajectory and previous weight-loss interventions.

• Factors affecting the feasibility and durability of behavioural change.

Physical Examination

The examination should include:

• Waist circumference.

• Blood pressure.

• Assessment for central adiposity.

• Inspection for acanthosis nigricans and lipoatrophy.

• Evaluation for clinical evidence of obesity-related cardiovascular or respiratory complications.

Waist circumference requires careful interpretation because the relation between waist size, visceral fat and cardiometabolic risk differs between populations. Central obesity remains clinically important even when overall body weight is not markedly elevated.

Diagnostics

Laboratory Assessment

Fasting lipid and glucose measurements are required to determine whether metabolic syndrome is present. Additional testing should be individualized according to the clinical context and may include:

• ApoB.

• High-sensitivity C-reactive protein.

• Fibrinogen.

• Uric acid.

• Urinary albumin/creatinine ratio.

• Liver-function tests.

The assessment of dyslipidaemia should recognize that insulin resistance commonly produces elevated triglyceride-rich lipoproteins, low HDL cholesterol and increased small, dense LDL particles. In diabetes, apoB measurement or non-HDL cholesterol calculation may estimate atherogenic risk more accurately than LDL cholesterol concentration alone.

Assessment for Associated Disease

A sleep study is indicated when symptoms of obstructive sleep apnoea are present.

When polycystic ovary syndrome is suspected from clinical features and anovulation, testosterone, luteinizing hormone and follicle-stimulating hormone should be measured.

Metabolic dysfunction-associated fatty liver disease may be evaluated further with the MAFLD fibrosis score, including FIB4, or with elastography.

The source material does not describe a specific role for electrocardiography, echocardiography, stress testing, coronary computed tomography or invasive electrophysiology in the diagnosis of metabolic syndrome. Cardiovascular investigations should therefore be directed by clinical evidence of established or subclinical cardiovascular disease rather than by the metabolic syndrome label alone.

Biomarkers and Laboratory Findings

The characteristic biochemical pattern is variable but commonly includes:

These biomarkers are associated abnormalities rather than universal diagnostic requirements. Additional testing should be selected according to the patient’s phenotype and suspected complications.

Clinical Significance

Cardiovascular Disease

In individuals without diabetes, metabolic syndrome is associated with an approximately 1.5- to 3-fold relative risk of new-onset cardiovascular disease. In comparative analyses, diabetes and hypertension confer stronger risks for acute myocardial infarction than several other individual components. The incremental cardiovascular risk attributable to the syndrome beyond the combined effects of its individual components remains uncertain.

Metabolic syndrome is also associated with increased risks of stroke and peripheral vascular disease. Heart failure may coexist, but is commonly related to metabolic-syndrome-associated atherosclerotic cardiovascular disease or hypertension. The association with cardiovascular disease may be stronger in women than in men.

High-sensitivity C-reactive protein provides additional prognostic information in some populations. Metabolic syndrome accompanied by increased hsCRP has been associated with increased all-cause mortality, although fewer than half of deaths in the cited cohort were cardiovascular.

Type 2 Diabetes

The risk of type 2 diabetes is increased approximately three- to fivefold among patients with metabolic syndrome. In the Framingham Offspring Study, metabolic syndrome accounted for a substantial population-attributable risk of incident diabetes, although fasting plasma glucose explained most or all of the observed excess risk.

Renal and Cardiac-Kidney-Metabolic Disease

Obesity, hyperglycaemia, dyslipidaemia and hypertension contribute to the development and progression of diabetes, chronic kidney disease and cardiovascular disease. Obesity and hypertension promote left-ventricular hypertrophy and kidney injury. In advanced kidney failure, concentric left-ventricular hypertrophy is highly prevalent, and anaemia increases myocardial oxygen demand, contributing to heart-failure progression.

Other Associations

Metabolic syndrome is associated with:

• Metabolic dysfunction-associated fatty liver disease and steatohepatitis.

• Polycystic ovary syndrome.

• Obstructive sleep apnoea.

• Hyperuricaemia.

• Albuminuria.

• Prothrombotic and inflammatory states.

• Alzheimer’s disease.

The degree to which these associations represent effects of the syndrome itself, rather than the cumulative impact of its individual components, remains variable and in some settings unresolved.

Treatment and Management

Treatment Principles

Management is directed at the underlying excess adiposity and at each uncontrolled cardiometabolic component. Weight reduction is the primary intervention because abdominal obesity is a major driver of insulin resistance and the syndrome. A reduction of at least 5%, and preferably 10%, improves insulin sensitivity and favourably modifies multiple components.

Treatment requires sustained lifestyle change, appropriate pharmacotherapy for residual risk and, in selected patients, metabolic or bariatric surgery. Management should also identify and treat established cardiovascular, renal, hepatic and respiratory complications.

Lifestyle Intervention

Caloric Restriction and Dietary Pattern

Caloric restriction is the most important component of weight loss. Dietary adherence is more important than the precise dietary composition because carbohydrate-restricted diets, although associated with more rapid initial weight loss, produce little or no advantage over caloric restriction alone after one year.

A high-quality dietary pattern emphasizing fruits, vegetables, whole grains, lean poultry and fish is preferred. Low-carbohydrate diets enriched in saturated fat are a concern, particularly in individuals at risk for atherosclerotic cardiovascular disease.

Physical Activity

Physical activity is important for maintaining weight loss and produces health benefits even when weight reduction is modest. Inactive individuals should increase activity progressively to improve adherence and reduce injury risk. At least 30 minutes of moderate-intensity activity daily provides health benefit; approximately 60–90 minutes of moderate- to high-intensity activity daily may be required to achieve meaningful weight reduction.

Activity may include walking, gardening, housecleaning and other routine activities rather than formal exercise alone. Some high-risk patients require formal cardiovascular evaluation before beginning an exercise programme.

Behaviour Modification

Behavioural programmes combine dietary restriction with increased activity and require prolonged follow-up because weight regain is common. Long-term support may be provided through individual or group counselling, internet-based programmes, social media and telephone contact.

Pharmacological Weight Management

Weight-loss pharmacotherapy may be considered when lifestyle intervention is insufficient. The source material identifies two broad classes: appetite suppressants and absorption inhibitors.

Greater weight loss generally produces greater improvement in metabolic syndrome components and may reduce progression from prediabetes to type 2 diabetes. GLP-1 receptor agonists may benefit metabolic dysfunction-associated fatty liver disease, although this indication is not described as FDA approved in the source material.

Metabolic and Bariatric Surgery

Metabolic or bariatric surgery is an important option for patients with a BMI greater than 40 kg/m2 or greater than 35 kg/m2 with comorbidities. Its use is evolving in patients with a BMI as low as 30 kg/m2 and type 2 diabetes.

Gastric bypass and vertical sleeve gastrectomy produce marked weight reduction and improve most metabolic syndrome features. A survival benefit has also been reported with gastric bypass.

Management of Individual Cardiometabolic Components

The available guidance emphasizes comprehensive risk-factor management:

• Lifestyle intervention should address weight, glycaemia, blood pressure and lipids simultaneously.

• Hypertension should be managed according to established hypertension guidance, with a stated target below 130/80 mmHg in the cardiovascular-kidney-metabolic framework.

• Statin therapy should be maximized in patients at intermediate or higher atherosclerotic cardiovascular risk.

• Ezetimibe may be used in high-risk patients.

• Triglycerides of at least 500 mg/dL may prompt consideration of fibrates.

• In patients with diabetes, triglycerides of 135–499 mg/dL and additional risk factors, eicosapentaenoic acid may be considered.

• Persistent or progressive impaired glucose tolerance despite intensive lifestyle intervention may prompt consideration of metformin.

• A GLP-1 receptor agonist is emphasized in patients with BMI at least 35 kg/m2 or HbA1c at least 9% or those requiring high insulin doses.

• An SGLT2 inhibitor is emphasized in chronic kidney disease.

• In diabetes with albuminuria, an ACE inhibitor or angiotensin-receptor blocker should be prioritized.

• In diabetic kidney disease with residual albuminuria greater than 30 mg/g despite ACE-inhibitor or angiotensin-receptor-blocker therapy, finerenone may be added; it may be used on a background of SGLT2-inhibitor therapy.

• Aspirin is favoured in selected patients with coronary artery calcium greater than 100 when bleeding risk is low.

• Additional agents, including PCSK9 inhibitors, GLP-1 receptor agonists and icosapent ethyl, may be selected according to the individual cardiovascular-kidney-metabolic profile.

The stated renal thresholds are an estimated glomerular filtration rate of at least 20 mL/min/1.73 m2 for safe initiation of an SGLT2 inhibitor, at least 30 mL/min/1.73 m2 for metformin, and greater than 25 mL/min/1.73 m2 with potassium below 5 mEq/L for likely initiation of finerenone.

Guideline Recommendations

A contemporary cardiovascular-kidney-metabolic approach recommends:

• Systematic screening for excess or dysfunctional adiposity and established cardiometabolic risk factors.

• Intensive lifestyle intervention when metabolic syndrome is identified.

• Comprehensive management of weight, glucose, blood pressure and lipids rather than isolated treatment of a single abnormality.

• Use of pharmacotherapy for persistently uncontrolled components.

• Screening for obstructive sleep apnoea and polycystic ovary syndrome when clinically indicated.

• Assessment for kidney disease, albuminuria, fatty liver disease and subclinical cardiovascular disease in appropriate patients.

• Use of ACE inhibitors or angiotensin-receptor blockers in chronic kidney disease with albuminuria and in diabetic kidney disease.

• Use of SGLT2 inhibitors in chronic kidney disease, with or without diabetes.

• Consideration of GLP-1 receptor agonists, statins, ezetimibe, finerenone, fibrates, eicosapentaenoic acid and other agents according to risk profile and residual abnormalities.

• Consideration of metabolic surgery when BMI and comorbidity thresholds are met.

• Interdisciplinary care involving obesity medicine, dietetics, pharmacy, mental-health services, community health workers and care managers when required.

The broader cardiovascular-kidney-metabolic framework also stresses improved sleep, tobacco cessation, physical activity, healthy dietary patterns, cholesterol control, blood-pressure control and social-determinants-of-health assessment.

Prognosis and Follow-Up

Metabolic syndrome signals substantially increased future risk of type 2 diabetes and cardiovascular disease. Its prognosis depends not only on the syndrome label but also on the severity and duration of individual components, particularly hyperglycaemia, hypertension, atherogenic dyslipidaemia, obesity and kidney disease.

Follow-up should be long term because weight regain frequently follows successful weight reduction and because metabolic abnormalities may progress despite initially limited symptoms. Ongoing assessment should include:

• Waist circumference and body weight.

• Blood pressure.

• Fasting glucose and lipid profile.

• Glycaemic progression where impaired glucose regulation is present.

• Urinary albumin/creatinine ratio when kidney risk is suspected.

• Liver assessment when metabolic dysfunction-associated fatty liver disease is possible.

• Symptoms of obstructive sleep apnoea.

• Features of polycystic ovary syndrome when relevant.

• Adherence, adverse effects and response to weight-loss medication.

• Cardiovascular, renal and heart-failure manifestations.

The intensity of follow-up should reflect global cardiometabolic risk and the presence of subclinical or overt cardiovascular-kidney-metabolic disease. Sustained behavioural support and coordinated multidisciplinary care are central to maintaining weight loss, controlling residual risk and improving long-term outcomes.